Stockreport

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Century Therapeutics, Inc.  (IPSC) 
PDF – Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overal [Read more]